Juan Rigla

Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA.

Datascope Corp. manufactures and distributes surgical equipments. The company provides medical instruments such as intra aortic balloon pumps and catheters for use in cardiology, radiology, anesthesiology, cardiovascular, vascular surgery and emergency medicine. It also develops vascular grafts and patches for reconstructive blood vessel surgeries as well as multifunction patient monitoring devices. The company was founded in 1964 as New York Corp. It is headquartered in Montvale, NJ.

Curon Medical, Inc. develops, manufactures and markets proprietary products for the treatment of gastrointestinal disorders. Its products consist of radiofrequency generators and single-use disposable devices. The company was founded on May 1, 1997 and is headquartered in Fremont, CA.

Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA.

Velocimed LLC develops, manufactures, and markets medical devices. The firm's products are used in cardiology and neurology applications. The company was founded in 2001 by Jay Schmelter, Michael Berman, and Dennis W. Wahr and is headquartered in Maple Grove, MN.

Arsenal Medical Inc. develops therapeutic products based on BioActive Composites platform. Its biomaterials-based systems provide targeted local and systemic therapies to treat chronic diseases and conditions. The firm product offers tailored dosing of drugs, mechanical and biochemical compatibility with tissues and complete bioabsorption. The company was founded by George M. Whitesides, Carmichael S. Roberts Jr. and Robert S. Langer Jr. in 2005 and is headquartered in Watertown, MA.

UltraShape, Inc. manufactures and markets non-invasive devices for the aesthetic medical field. The company was founded by Betsy S. Atkins and Glicksman Ami in 2000 and is headquartered in San Ramon, CA.

BeneChill, Inc. develops non-invasive cooling technology for cerebral ischemia treatment. The company was founded by Michael L. Berman and Denise Barbut in 2004 is headquartered in San Diego, CA.

InspireMD Ltd. is a medical device company, which engages in the development and commercialization of platform technology for the treatment of vascular and coronary disease. It offers MicroNet stent, a device designed to trap and seal thrombus and plaque against the vessel wall, preventing embolization. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Bridgepoint Medical, Inc. develops interventional technology in the field of cardiology. It focuses on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. The company was founded by Michael L. Berman, Chad J Kugler and Robert E Atkinson in 2005 and is headquartered in Plymouth, MN.

UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only.

Creare, Inc. provides engineering research, development and consulting services. The firm specializes in fluid dynamics and heat transfer, cryogenics, robotics, data systems, advanced materials, control systems, and aerospace and biomedical engineering. Its projects range from analysis and computational modeling to prototype fabrication and testing. The company was founded in 1961 and is headquartered in Hanover, NH.

ClearCut Medical Ltd. develops proprietary technology and tools for removal of cancer. Its product ClearSightTM MRI System, focuses on breast cancer lumpectomy for intraoperative margin assessment of surgically removed lumps. The firms applications include breast cancer biopsies, margin assessment of skin cancer, prostate cancer, colorectal cancer and lung cancer tissue microstructure. The company was founded by Eyal Kolka and Erez Golan in 2010 and is headquartered in Rehovot, Israel.

EndoSpan Ltd. develops novel endovascular system for endovascular aortic aneurysm repair. The firm is opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The company was founded by Rafi Benary and Alon Shalev in 2009 and is headquartered in Herzlia, Israel.

CardiacSense Ltd. is a digital health company based in Caesarea, Israel. The Israeli company has developed a medical watch that integrates proprietary patent-protected sensors and software algorithms to provide continuous measurement of parameters such as core temperature, respiratory rate, blood pressure, oxygen saturation, and heart rate at CE and FDA-mandated accuracies. This provides an alternative to costly and complex invasive devices, addressing the increasing demand for remote patient monitoring and tele-health. The private company was founded in 2009 by Eldad Shemesh and Liat Shemesh, with Eldad Shemesh serving as the CEO since incorporation.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

Part of Medtronic Plc, Mazor Robotics LLC is a company that specializes in the Mazor X Stealth Edition robotic guidance platform. The company is based in Orlando, FL. The platform is equipped with advanced software, robotic technologies, navigation, and instrumentation to support predictable surgical procedures. Christopher Prentice has been the CEO of the company since 2014.